CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Syra Health Q3 revenue jumps to record high on workforce contracts

By Reuters News


Overview

  • US healthcare solutions firm's Q3 revenue rose 52% yr/yr to record high

  • Company posted third consecutive profitable quarter, with EPS swinging to $0.02 from loss

  • Gross margin reached record 46.3%, driven by favorable revenue mix and operating leverage


Outlook

  • Syra Health expects to achieve full-year profitability in 2026

  • Company anticipates quarter-to-quarter variability due to timing of awards and contract milestones

  • Approval for Syrenity in CMS ACCESS Model expected to be a consistent revenue source over next decade


Result Drivers

  • POPULATION HEALTH SOLUTIONS - Co said high-margin population health solutions led Q3 growth, rising 52% yr/yr

  • WORKFORCE CONTRACTS - Healthcare workforce revenue increased 50% as co prioritized contracts with stronger margins

  • REVENUE MIX AND OPERATING LEVERAGE - Gross margin expansion attributed to favorable revenue mix and ongoing operating leverage


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

$2.60 mln

Q3 EPS

$0.02

Q3 Gross Margin

46.30%


Reuters Recommended Reads

  • Nov 3 - AdaptHealth posts Q3 loss due to goodwill impairment charge

  • Nov 3 - Strata Critical Medical Q3 revenue beats estimates; announces buyback

  • Nov 3 - Sotera Health Q3 revenue beats estimates on pricing and volume


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.